Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

Clinical Pearls for Vitiligo and Pigmentation Complexities: Part 1

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Q&A: Amy McMichael, MD, Discusses 48-Week VISIBLE Study Results on Psoriasis in Patients With Skin of Color

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss results of an open-label phase 3b/4 study for atopic dermatitis.

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP 

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

Phase 2b Trial Reinforces Zasocitinib’s Safety Profile

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Las Vegas - Chemical peels are experiencing a new wave of popularity now that the downsides of laser peels have become better known, James M. Spencer, M.D.

Performing Office Peels